RxDoctor Payments Data

Elisa Rogowitz, MD

Internal Medicine · Lakewood, CONPI 1407268360

Payments from drug & device makers

$1,523in general payments, 2019–2025

Across 68 payments — averaging $22.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$812
  • BETA Bionics, Inc.$213
  • Neurocrine Biosciences, Inc.$200
  • Medtronic$97
  • Tandem Diabetes Care, Inc.$74
  • Astellas Pharma US Inc$33
  • plus $93 from 4 others

What the payments were for

  • Consulting fees$20013%
  • Food & beverage$1,12374%
  • Education$20013%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,523 in reported general payments places this provider in the 85th percentile of 1,430 internal medicine providers in Colorado.

See all internal medicine providers in Colorado

Medicare billing

Part B allowed, 2024
$36,757
Medicare patients
94
Services billed
405

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin68$85,984
MounjaroTirzepatide48$77,843
OzempicSemaglutide61$74,945
Levothyroxine Sodium176$51,810
TrulicityDulaglutide17$24,830
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog11$16,579
Cinacalcet Hcl21$16,149
Fiasp FlextouchInsulin Aspart (Niacinamide)15$15,383
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog25$12,344
Lantus SolostarInsulin Glargine,hum.Rec.Anlog44$7,538
Humalog Kwikpen U-100Insulin Lispro21$6,639
Novolog FlexpenInsulin Aspart23$5,537
Nano 2nd Gen Pen NeedlePen Needle, Diabetic38$4,038
TirosintLevothyroxine Sodium11$3,139
SynthroidLevothyroxine Sodium58$2,689

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$31$102,67365 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,430 internal medicine providers in Colorado.

Other internal medicine in Lakewood

See the full list for Colorado

Where these figures come from

Is this you, or does something look wrong? →